⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
globenewswire.com
GSK
JNJ
AZN
SPARK NS Selects Nine Projects to Receive in Total Up to $18 Million in Funding to Advance Academic Discoveries in Autism and Parkinson’s Disease from the Lab to the Clinic
globenewswire.com
NVS
MRK
BMY
LLY
ABBV
JNJ
AZN
GILD
BIIB
REGN
AMGN
VRTX
Lung Cancer Research Foundation Launches Small Cell Lung Cancer Grants in Collaboration with AstraZeneca
prnewswire.com
AZN
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
globenewswire.com
AZN
Microplastics Discovered in Prostate Tumors
prnewswire.com
PFE
AZN
BMY
XOM
Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions
businesswire.com
LLY
AMGN
AZN
MRK
PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions
prnewswire.com
REGN
AZN
BMY
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
globenewswire.com
AIM
AZN
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
globenewswire.com
AZN
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
businesswire.com
AZN